POET Technologies Scrambles to Rebuild Credibility After $400M Cash Injection and Legal Onslaught

POET raises $400M at premium but shares fall 12% on PFIC class actions, order cancellations, and CFO departure; Lumilens deal offers hope.

The optics could hardly be more contradictory. POET Technologies landed a $400 million direct share placement from a single institutional investor at a premium price of $21 per unit, yet the stock opened the following session deep in the red. By Monday’s close, shares had fallen to $14.01 — a daily loss of 12.27 percent — wiping out much of the recent surge that had carried the stock from $7.11 to $20.81 in just a handful of trading days.

The capital injection gives the photonics developer a formidable war chest. The company issued roughly 19 million new shares and threw in warrants exercisable at $26.25. Management plans to funnel the proceeds into expanding manufacturing infrastructure, making targeted acquisitions, and boosting research and development as it pushes an aggressive growth strategy in AI-related photonics. But the market’s frosty reception signals that investors see the legal and commercial headwinds piling up.

A string of US class-action lawsuits is now clouding the narrative. Plaintiffs accuse POET, CEO Suresh Venkatesan, and CFO Thomas Mika of inadequate disclosure regarding the company’s classification as a Passive Foreign Investment Company, a designation that can carry adverse tax consequences for US investors. The suits also point to a 303 percent increase in outstanding shares from late 2022 to early 2026, arguing that with minimal operating revenue, the PFIC status should have been flagged much earlier. One action covers purchasers from April 1, 2026, to 8:57 a.m. on April 27, 2026 — the moment the PFIC risk became public.

Adding to the legal turmoil, investors allege that a leadership leak caused Marvell Semiconductor’s subsidiary, Celestial AI, to cancel all outstanding orders. When the cancellation was announced in late April, POET’s stock cratered by 45 percent in a single session. Marvell has cited confidential matters regarding orders and shipping details, declining to elaborate further.

To address the PFIC issue going forward, POET’s board has approved a plan to shift the company’s legal domicile to the United States. If shareholder approval is required, the matter is slated for the annual meeting on June 26, 2026. The lead plaintiff deadline in the class actions falls just three days later on June 29 — a tight window that will test the company’s ability to manage multiple simultaneous pressures.

Operationally, there are genuine bright spots. POET secured a strategic supply agreement with Lumilens, starting with an initial order worth $50 million. The framework contract could expand to more than $500 million over five years, providing a meaningful counterweight to the legal noise. First-quarter revenue rose to $503,000 from $167,000 a year earlier, although the net loss widened to $12.3 million — or $0.08 per share. Analysts had expected slightly lower revenue but a smaller loss, leaving some room for disappointment.

The management suite is also in flux. Thomas Mika, CFO for the past decade, has announced his retirement this year. Meanwhile, Dr. Sandeep Kumar, a 18-year veteran of Silicon Labs, has stepped in as chief operating officer to spearhead manufacturing ramp-up in Malaysia.

Between now and the end of June, the news flow hinges on two sharp inflection points: the shareholder vote on the US relocation and the lead plaintiff deadline in the securities suits. Any positive delivery updates from the Lumilens contract could steady the operational narrative, while fresh legal filings would almost certainly renew selling pressure on the battered stock.